✎ Add Post
Please take a few minutes to sign a letter for better HVC Treatment Access. Feel free to re-distribute or share this page.
Stanford Esophageal Multi-Disciplinary Program in Innovation and Research presents our Second Annual Symposium:
There is a growing interest in the discovery and development of new therapeutics that will cure chronic hepatitis B virus (HBV) infection, due to the recent establishment of new cell...
A key target for new HBV therapies
Information of HCC biomarkers, AFP-L3, AFP and DCP (same as PIVKA II) assays on uTASWako i30 automated analyzer. As you can see, AFP-L3 and/or DCP elevated more than cut-off values...
The Division of Gastroenterology & Hepatology, Department of Medicine - Stanford University School of Medicine
Dynavax’s HEPLISAV-B™ [Hepatitis B Vaccine (Recombinant), Adjuvanted] Recommended by CDC Advisory Committee on Immunization Practices for the Prevention of Hepatitis B in Adults.